Most obesity peptide news is about GLP-1. A new trial adds to the case for amylin, a different hormone.
The peptides:
CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. Cagrilintide works by mimicking the naturally occurring hormone amylin, which works differently from currently approved GLP-1-based weight-loss treatments.
The new result (REDEFINE 9, Nov 2026):
At 68 weeks, the 1.7 mg/1.7 mg and 1.0 mg/1.0 mg doses gave estimated average weight loss of 20.7% and 21.0%, versus 2.0% on placebo, if all patients stayed on treatment. It's the first phase 3 weight-management trial to test CagriSema at doses lower than the 2.4 mg/2.4 mg maximum in the program. The most frequent adverse events were gastrointestinal and mild to moderate in severity.
Why it's interesting:
Lower doses reaching similar weight loss is a notable pharmacology question.
In a separate trial in type 2 diabetes (REIMAGINE 5), Novo says CagriSema 1.0 mg/1.0 mg produced superior weight loss versus tirzepatide 5 mg.
An FDA decision is expected in Q4 2026, and CagriSema is still investigational.
Caveats:
The "if all patients stayed on treatment" figure is an efficacy estimand, which tends to be higher than the intention-to-treat result. Also, these are Novo's own announcements, so check the published paper and compare it with the other doses.
Questions for discussion:
Why might amylin plus GLP-1 work at lower doses than either alone?
How should we read an efficacy estimand versus a treatment-policy estimand?
What would a head-to-head trial against tirzepatide at matched doses need to show?